BioGaia AB (BioGaia) develops, manufactures, and sells probiotic products for gut, oral, and immune health. The products are based on the lactic acid bacterium Lactobacillus reuteri (Reuteri) which has probiotic and health-enhancing effects. The company’s product portfolio includes probiotic tablets with vitamin D, capsules, chewable tablets, oral rehydration solution (ORS), drops, lozenges and powder

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

BioGaia's initiatives focus on advancing probiotic research, with a strong emphasis on the lactic acid bacterium Limosilactobacillus reuteri. The company invests in its net sales in research and development, conducting high-quality pre-clinical models and clinical studies that are condition-based, such as colic or constipation. BioGaia collaborates with a global network of universities and hospitals to promote transparency and high standards of scientific reporting, aiming to publish all studies regardless of their outcome. The company has developed innovations like LongevityGuard, a patented desiccant technology, and EvidenceBiotics, a premium classification for probiotics that meet high standards of quality, safety, and clinical validation. The R&D unit of BioGaia is the BioGaia Centre of Excellence, located in Sweden. This laboratory serves as a hub for research and product development, enabling the company to perform small-scale trials and production. It contributes to a deeper understanding of bacterial functions and the development of sustainable probiotic products, focusing on growing and stabilizing probiotic strains. In FY2025, the company spent SEK115.7 million on its R&D activities, which was 7.5% of its revenue.